Despite a poor prognosis and resistance to chemotherapy, new targeted therapies based on genetic mutations are improving outcomes for patients with biliary tract cancer.

The global cholangiocarcinoma market is rapidly evolving due to rising disease incidence, enhanced diagnostics, and new treatment strategies. This rare bile duct cancer often presents late, driving ...

• Key Intrahepatic cholangiocarcinoma pipeline therapies in various stages of development include Zanidatamab, Derazantinib, MIV-818, Bemarituzumab, KIN-3248, TYRA-200, Nelitolimod, and others.

Cholangiocarcinoma, also known as bile duct cancer, is a rare disease. It's a devastating condition incurable at the point ...

Background Cholangiocarcinoma (CCA) is a highly lethal malignant tumour with increasing incidence. Current therapies exhibit ...

Optimism Remains as Cholangiocarcinoma Becomes the ‘Poster Child’ for Targeted Therapy Even though cholangiocarcinoma is a rare cancer, Valle said that he is still optimistic about the future of the ...

A new understanding of the genetic mutations that drive the rare and difficult-to-treat cancer cholangiocarcinoma, along with the testing of targeted drugs and immunotherapies in people with the ...

Results showed that across 3,038 U.S. counties there were 85,909 cholangiocarcinoma cases and 23,902 cholangioscopies performed — an annual mean volume of 2.5 (standard deviation, 7.1 ...

Cholangiocarcinoma is a relatively rare adenocarcinoma of the bile ducts that is rapidly fatal unless it can be completely resected. In most cases, the tumor is too advanced for resection by the ...

The magnetic resonance (MR) imaging appearance of cholangiocarcinoma depends on the amount of fibrosis, necrosis, and mucinous material within the tumor. Most frequently it appears as a ...

Intraductal neoplasms of the bile duct are macroscopically characterized by exophytic or polypoid growth patterns and have a favorable prognosis. Although some tumors with a predominantly tubular ...